What is the NICE guidance around clinical decision-making?

Privacy policy – You must make sure the relevant privacy policies deal with how you will process Covid-19 data. You should have an employee privacy policy and this may already deal with health data (if it doesn’t, it should). You might also need to look at privacy policies for customers, visitors and suppliers. This ensures that processing is lawful, fair and transparent.

Lawful processing conditions – You will need to consider which processing conditions you are relying on (remembering that you need both an Article 6 condition and an Article 9 condition – this is the part of the GDPR which deals with special category data). As a lot of the data you collect will be about employees, you can’t use consent so you will have to find another lawful reason under GDPR which allows you to process the data.

Appropriate policy document – When you are considering your Article 9 processing conditions, remember you must also have an “appropriate policy document” in place.

Processing record – Finally make sure your processing record is up to date with information on what data you collect and use.

Read more about this

The Government has produced and published three new Procurement Policy Notes as a direct result of the ever changing Covid-19 environment.

PPN 01/20: Responding to COVID-19

The purpose of PPN 01/20 is to ensure that contracting authorities are able to procure goods, services and works with extreme urgency, to allow them to respond to the pandemic efficiently.

This PPN provides guidance for the following circumstances:

• Direct award due to extreme urgency (regulations 32(2)(c)) (click here to read our article regarding regulation 32)
• Direct award due to an absence of competition or protection of exclusive rights
• Call off from an existing framework agreement or dynamic purchasing system
• Call for competition using a standard procedure with accelerated timescales
• Extending or modifying a contract during its term

PPN 02/20: Supplier relief due to COVID-19

PPN 02/20 focuses predominantly on the supplier to assist in keeping supply chains open and ensuring that suppliers are kept financially sound during these unpredictable times.

This PPN provides guidance for the following circumstances:

• Urgent reviews of contract portfolios and to update suppliers if they believe they are at risk
• Put in place appropriate payment measure to support supplier cash flow
• Where contract payments are based on ‘payment by results’ make payments based on previous invoices
• Ask suppliers to act on a ‘open book’ basis and make cost data available to the contracting authority during this period
• Ensure invoices submitted by suppliers are paid immediately on receipt

PPN 03/20: Use of Procurement Cards

The third guidance note PPN 03/20 relates to the use of procurement cards to increase efficiency and accelerate payment to suppliers.

This PPN provides the following advice and urges organisations to arrange with their procurement card provider to:

• Increase a single transaction limit to £20,000 for key card holders
• Raise monthly limits on spending with procurement cards to £100,000 for key card holders
• Spend on procurement cards each month in excess of £100,000 should be permissible to meet business needs

Although the above advice has been provided, should these limits not be necessary, organisations should seek an appropriate transaction limit or monthly limit.

The PPN also advises that by 30 April 2020, in scope organisations should:

• Ensure that a number of appropriate staff have the authority to use these cards
• Open all relevant categories of spend to enable these cards to be used more widely

Read more about this

• Start critical care treatment with a clear plan of how the treatment will address the diagnosis and lead to agreed outcomes.
• Review critical care treatment regularly and when the patient’s clinical condition changes.
• Stop critical care treatment when it is no longer considered able to achieve the desired outcomes. Record the decision and the discussion with family, carers and the patient (if possible).

Read more about this

Suspension should always be a last resort and not a knee jerk reaction. We would not advise suspension unless a the above steps around the risk assessment have been undertaken. Depending on your local policies, suspension could then be an option on the basis that their health and safety and the health and safety of others are put at risk by their actions.

Read more about this

In our latest “in conversation” webinar we discussed the outlook for the corporate transaction market. Whilst it would be a brave person to predict the future of anything at the moment given current circumstances, we were joined by two organisations who are very well placed to provide their views.

John Laud, Head of Corporate Banking for North and West Yorkshire for Barclays, his colleague Stephen Loureda from their Credit Analysis Team, and Jill Williams, Investment Director of Mercia Asset Management’s Growth Fund, were in conversation with Ward Hadaway corporate partners Adrian Ballam and Jonathan Pollard to share their thoughts about how the ‘new normal’ for the transactions market may look:

• With supply chain and forecast prediction challenges, how will banks and investors determine what represents a sound opportunity?
• How will distressed and opportunistic acquisition opportunities be funded, and what is investor appetite for such opportunities?
• How have seller and buyer pricing expectations been impacted as a result of the pandemic?
• How are funders reacting, and how should ambitious businesses respond to the very low, or even negative, interest rates?

We expect this video to be of real value to those businesses whose plans of buying, selling or investment may have been impacted by the current economic crisis, but who are looking at opportunities to determine how they may shape their futures – #gettingbacktobusiness.

Read more about this